Bracco Imaging Announces Publication of Data Reinforcing Efficacy, Safety of Gadopiclenol in Contrast-Enhanced MRI of Certain Body Regions
Bracco Imaging has issued a statement on new results published in the journal Radiology which found that gadopiclenol (VUEWAY), which has half the dose (or the amount) of gadolinium found in other available gadolinium-based contrast agents, provides similar lesion visualization and contrast enhancement compared with gadobuterol (Gadavist).
Source: itnonline.com